Clinical Trial Update: M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

This is a Phase 1 trial updating the safety and dosing of M6620 in combination with irinotecan in patients with metastatic or unresectable solid tumors. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer
• Small Cell Lung Cancer

Drugs mentioned

• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• M6620 (berzosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING